CytoDyn's Leronlimab Shows Promise in Glioblastoma Combination Therapy
Event summary
- CytoDyn presented preclinical data at the AACR Special Conference on March 23, 2026, showing leronlimab enhances temozolomide and radiation response in glioblastoma.
- CCR5 expression correlated with poor prognosis and tumor core features in 154 primary GBM tumors.
- Leronlimab demonstrated synergy with standard-of-care therapies, reducing oxygen consumption rate in a dose-dependent manner.
- CytoDyn plans to initiate a pilot study evaluating leronlimab in glioblastoma.
The big picture
CytoDyn's data suggests CCR5 inhibition could address a major unmet need in glioblastoma, where resistance to standard therapies is common. The findings align with broader trends in oncology toward combination therapies targeting the tumor microenvironment. Success in glioblastoma could expand leronlimab's potential beyond its current focus on metastatic breast and colorectal cancers.
What we're watching
- Clinical Translation
- Whether preclinical synergy with temozolomide and radiation translates into clinical efficacy in glioblastoma patients.
- Regulatory Pathway
- The pace at which CytoDyn advances leronlimab through regulatory approvals for glioblastoma.
- Competitive Positioning
- How CytoDyn differentiates leronlimab in the crowded oncology space, particularly against other CCR5 inhibitors.
Related topics